http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111755067-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b131d4978e15ad33febc57d22cc766f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B30-00 |
| filingDate | 2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_673c74ca7c61f76e28d6562a864839bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9e404e8877e6a3a3f58a4cd55e2f945 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ec615cf94e162c81c69759358aa8e46 |
| publicationDate | 2020-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111755067-A |
| titleOfInvention | Screening method of tumor neoantigen |
| abstract | The invention discloses a method for screening tumor neoantigens, aiming at solving the problem that the existing method can not screen high-quality tumor neoantigens from multiple angles. The method comprises the following specific steps: step one, selecting a variation type of a tumor; step two, RNA variation analysis is carried out on the tumor; step three, carrying out MHC molecule analysis on normal blood and tumor; step four, RNA expression analysis is carried out on the tumor; fifthly, carrying out variation annotation on the tumor; analyzing the variation driving gene of the tumor; seventhly, predicting the HLA molecule binding affinity of the tumor; step eight, analyzing the mutation frequency of the tumor; step nine, comprehensively scoring the tumor neoantigens; step ten, analyzing the synthesis difficulty of the tumor neoantigen; step eleven, comprehensively selecting the final tumor neoantigen. The invention optimally combines tumor mutation analysis and tumor expression prediction tumor specific antigen, so that the analysis process is more efficient and accurate. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113517021-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113517021-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114882951-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114882951-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113322233-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112466396-A |
| priorityDate | 2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID43672 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535645 |
Total number of triples: 23.